- Open
- 0.88
- High
- 0.95
- Low
- 0.84
- Close
- 0.95
- Change
- -0.08 (-8.57%)
- Volume
- 444,646
| 1 Oct 2026 | 07:00:04 | Strengthening pipeline prominent US institutions |
| 15 Sept 2026 | 07:00:06 | Adoption of Advanced Brain Tumor Imaging Platform |
| 28 Aug 2026 | 07:00:04 | US Academic Medical Centre Adopts IB Clinic |
| 29 Jul 2026 | 07:00:01 | Half Yearly Report to 30 June 2026 |
| 14 Jul 2023 | Annual Report Year Ended 31 December 2022 | |
| 27 Apr 2023 | Annual Report Year Ended 31 December | |
| 20 Apr 2021 | Annual Report 2020 |
Imaging Biometrics Limited develops advanced imaging solutions for the medical field, focusing on the treatment and management of brain tumors. The company offers products such as IB Clinic, an automated imaging platform designed for high-volume cancer centers, and IB Zero G, which enhances MRI images using non-contrast inputs. Imaging Biometrics generates revenue through fee-per-exam processing services and commercial contracts with healthcare providers, including independent diagnostic imaging centers. The company operates primarily in the United States and is engaged in clinical trials and partnerships to expand its market presence.
| 1 Oct 2026 | 07:00:04 | Strengthening pipeline prominent US institutions |
| 15 Sept 2026 | 07:00:06 | Adoption of Advanced Brain Tumor Imaging Platform |
| 28 Aug 2026 | 07:00:04 | US Academic Medical Centre Adopts IB Clinic |
| 29 Jul 2026 | 07:00:01 | Half Yearly Report to 30 June 2026 |
| 14 Jul 2023 | Annual Report Year Ended 31 December 2022 | |
| 27 Apr 2023 | Annual Report Year Ended 31 December | |
| 20 Apr 2021 | Annual Report 2020 |
Imaging Biometrics Limited develops advanced imaging solutions for the medical field, focusing on the treatment and management of brain tumors. The company offers products such as IB Clinic, an automated imaging platform designed for high-volume cancer centers, and IB Zero G, which enhances MRI images using non-contrast inputs. Imaging Biometrics generates revenue through fee-per-exam processing services and commercial contracts with healthcare providers, including independent diagnostic imaging centers. The company operates primarily in the United States and is engaged in clinical trials and partnerships to expand its market presence.
| 14 Jul 2026 | 10:02:13 | Sub-division |
| 3 Jun 2026 |
| Imaging Biometrics says commercial momentum is 'genuine and measurable' |
| 14 Jul 2026 | 10:02:13 | Sub-division |
| 3 Jun 2026 |
| Imaging Biometrics says commercial momentum is 'genuine and measurable' |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £377m | -0.5% | |
| £66m | -0.3% | |
| £36m | -0.4% | |
| £5m | -0.8% | |
| £2m | -0.6% | |
IBAIImaging Biometrics Limited | £2m | -0.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £377m | -0.5% | |
| £66m | -0.3% | |
| £36m | -0.4% | |
| £5m | -0.8% | |
| £2m | -0.6% | |
IBAIImaging Biometrics Limited | £2m | -0.1% |